Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

Fabrice Chouraqui will step down as president of Novartis Pharmaceuticals U.S. at the end of August. Novartis AG (NYSE:NVS; SIX:NOVN) said he will be succeeded by 14-year Novartis veteran Victor Bulto, who is VP and head of the U.S. immunology, hepatology & dermatology franchise.

Cancer immunotherapy company iTeos Therapeutics S.A. (Gosselies, Belgium) hired Matthew Call as COO, with additional business development responsibilities. Call was COO of Endocyte Inc., which Novartis acquired last year...